• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从化合物中鉴定严重急性呼吸综合征冠状病毒2主要蛋白酶的潜在抑制剂:一项分子对接研究。

Identification of potential inhibitors of SARS-CoV-2 main protease from compounds: A molecular docking study.

作者信息

Mpiana Pius T, Ngbolua Koto-Te-Nyiwa, Tshibangu Damien S T, Kilembe Jason T, Gbolo Benjamin Z, Mwanangombo Domaine T, Inkoto Clement L, Lengbiye Emmanuel M, Mbadiko Clement M, Matondo Aristote, Bongo Gedeon N, Tshilanda Dorothée D

机构信息

Department of Chemistry, Faculty of Sciences, University of Kinshasa, P.O Box 190, Kinshasa 11, Congo.

Department of Biology, Faculty of Sciences, University of Kinshasa, P.O Box 190, Kinshasa 11, Congo.

出版信息

Chem Phys Lett. 2020 Sep;754:137751. doi: 10.1016/j.cplett.2020.137751. Epub 2020 Jun 30.

DOI:10.1016/j.cplett.2020.137751
PMID:33518775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833182/
Abstract

SARS-CoV-2 is the pathogen agent of the new corona virus disease that appeared at the end of 2019 in China. There is, currently, no effective treatment against COVID-19. We report in this study a molecular docking study of ten molecules with the main protease (3CLpro) responsible for the replication of coronaviruses. The outcome of their molecular simulation and ADMET properties reveal three potential inhibitors of the enzyme (ligands , and ) with a clear preference of ligand that has the highest binding energy (-7.9 kcal/mol) and fully obeys the Lipinski's rule of five.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是2019年底在中国出现的新型冠状病毒病的病原体。目前,尚无针对2019冠状病毒病(COVID-19)的有效治疗方法。我们在本研究中报告了十种分子与负责冠状病毒复制的主要蛋白酶(3CLpro)的分子对接研究。它们的分子模拟结果和药物代谢及毒性性质揭示了三种该酶的潜在抑制剂(配体、和),其中配体具有明显优势,其结合能最高(-7.9千卡/摩尔)且完全符合Lipinski的五规则。

相似文献

1
Identification of potential inhibitors of SARS-CoV-2 main protease from compounds: A molecular docking study.从化合物中鉴定严重急性呼吸综合征冠状病毒2主要蛋白酶的潜在抑制剂:一项分子对接研究。
Chem Phys Lett. 2020 Sep;754:137751. doi: 10.1016/j.cplett.2020.137751. Epub 2020 Jun 30.
2
Exploring the active constituents of in intervention of novel coronavirus (COVID-19) based on molecular docking method.基于分子对接方法探索[具体内容]在新型冠状病毒(COVID-19)干预中的活性成分。 (你提供的原文中“Exploring the active constituents of ”后面缺少具体物质,我按正常翻译思路补齐了这部分内容的中文表述方式,实际使用时请根据完整准确的原文进行调整。)
Netw Model Anal Health Inform Bioinform. 2021;10(1):8. doi: 10.1007/s13721-020-00279-y. Epub 2021 Feb 6.
3
Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.针对 SARS-CoV-2 主蛋白酶的潜在化合物的虚拟筛选、ADMET 预测和动力学模拟。
J Biomol Struct Dyn. 2021 Oct;39(17):6617-6632. doi: 10.1080/07391102.2020.1796812. Epub 2020 Jul 25.
4
validation of coumarin derivatives as potential inhibitors against Main Protease, NSP10/NSP16-Methyltransferase, Phosphatase and Endoribonuclease of SARS CoV-2.验证香豆素衍生物作为潜在抑制剂对 SARS-CoV-2 的主要蛋白酶、NSP10/NSP16-甲基转移酶、磷酸酶和内切核糖核酸酶的抑制作用。
J Biomol Struct Dyn. 2021 Nov;39(18):7306-7321. doi: 10.1080/07391102.2020.1808075. Epub 2020 Aug 24.
5
Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.基于分子对接的虚拟筛选从ZINC数据库中鉴定新型冠状病毒3CL蛋白酶的潜在抑制剂
Front Mol Biosci. 2020 Dec 17;7:603037. doi: 10.3389/fmolb.2020.603037. eCollection 2020.
6
Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic.筛选海洋藻类代谢产物作为严重急性呼吸综合征冠状病毒2主蛋白酶(3CLpro)的高亲和力抑制剂:一项计算机模拟分析,以确定对抗新冠疫情的新型候选药物。
Appl Biol Chem. 2020;63(1):79. doi: 10.1186/s13765-020-00564-4. Epub 2020 Nov 21.
7
In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.通过分子对接、MMGBSA 预测结合能计算和分子动力学模拟,从计算机上鉴定潜在的关键 SARS-CoV-2 3CL 水解酶(Mpro)抑制剂。
PLoS One. 2020 Jul 24;15(7):e0235030. doi: 10.1371/journal.pone.0235030. eCollection 2020.
8
In silico studies on stilbenolignan analogues as SARS-CoV-2 Mpro inhibitors.白藜芦醇木脂素类似物作为新型冠状病毒3C样蛋白酶抑制剂的计算机模拟研究
Chem Phys Lett. 2021 May 16;771:138563. doi: 10.1016/j.cplett.2021.138563. Epub 2021 Mar 22.
9
detection of potential inhibitors from vitamins and their derivatives compounds against SARS-CoV-2 main protease by using molecular docking, molecular dynamic simulation and ADMET profiling.通过分子对接、分子动力学模拟和ADMET分析从维生素及其衍生物化合物中检测针对SARS-CoV-2主要蛋白酶的潜在抑制剂。
J Mol Struct. 2022 Jun 15;1258:132652. doi: 10.1016/j.molstruc.2022.132652. Epub 2022 Feb 18.
10
Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2.整合虚拟筛选、药物信息学分析和分子动力学:鉴定针对新型冠状病毒3C样蛋白酶的潜在抑制剂
Front Mol Biosci. 2024 Mar 7;10:1306179. doi: 10.3389/fmolb.2023.1306179. eCollection 2023.

引用本文的文献

1
Aloe vera leaf extract as a sustainable route for silver nanoparticle synthesis with enhanced antimicrobial activity.芦荟叶提取物作为一种可持续的合成具有增强抗菌活性的银纳米颗粒的途径。
Sci Rep. 2025 Jul 2;15(1):22481. doi: 10.1038/s41598-025-05070-5.
2
Anatolian medicinal plants as potential antiviral agents: bridging traditional knowledge and modern science in the fight against COVID-19 and related viral infections.作为潜在抗病毒药物的安纳托利亚药用植物:在抗击新冠病毒及相关病毒感染中架起传统知识与现代科学的桥梁
Turk J Biol. 2024 Jun 26;48(4):218-241. doi: 10.55730/1300-0152.2699. eCollection 2024.
3
Medicinal plants used in Gabon for prophylaxis and treatment against COVID-19-related symptoms: an ethnobotanical survey.

本文引用的文献

1
As a potential treatment of COVID-19: Montelukast.孟鲁司特钠:治疗 COVID-19 的一种潜在药物。
Med Hypotheses. 2020 Sep;142:109828. doi: 10.1016/j.mehy.2020.109828. Epub 2020 May 11.
2
Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.针对可能抑制新型冠状病毒主要蛋白酶的临床导向药物的分子机制探索
J Phys Chem Lett. 2020 Jun 4;11(11):4413-4420. doi: 10.1021/acs.jpclett.0c00994. Epub 2020 May 21.
3
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
加蓬用于预防和治疗与 COVID-19 相关症状的药用植物:一项民族植物学调查。
Front Pharmacol. 2024 Jul 5;15:1393636. doi: 10.3389/fphar.2024.1393636. eCollection 2024.
4
Plants from Arid and Semi-Arid Zones of Mexico Used to Treat Respiratory Diseases: A Review.墨西哥干旱和半干旱地区用于治疗呼吸系统疾病的植物:综述
Plants (Basel). 2024 Mar 11;13(6):792. doi: 10.3390/plants13060792.
5
A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products.通过天然产物对抗 COVID-19:药物化学家的各种尝试的全面更新。
Molecules. 2023 Jun 20;28(12):4860. doi: 10.3390/molecules28124860.
6
A comprehensive perspective of traditional Arabic or Islamic medicinal plants as an adjuvant therapy against COVID-19.关于传统阿拉伯或伊斯兰药用植物作为对抗COVID-19辅助疗法的全面观点。
Saudi J Biol Sci. 2023 Mar;30(3):103561. doi: 10.1016/j.sjbs.2023.103561. Epub 2023 Jan 13.
7
LC-MS Based Phytochemical Profiling towards the Identification of Antioxidant Markers in Some Endemic Species from Mascarene Islands.基于液相色谱-质谱联用技术的植物化学图谱分析,用于鉴定马斯克林群岛一些特有物种中的抗氧化标记物。
Antioxidants (Basel). 2022 Dec 26;12(1):50. doi: 10.3390/antiox12010050.
8
Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study.表没食子儿茶素没食子酸酯和槲皮素与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突糖蛋白(S糖蛋白)的相互作用:计算机模拟研究
Biomedicines. 2022 Nov 29;10(12):3074. doi: 10.3390/biomedicines10123074.
9
Complementary medicines used in ulcerative colitis and unintended interactions with cytochrome P450-dependent drug-metabolizing enzymes.用于溃疡性结肠炎的补充药物与细胞色素 P450 依赖性药物代谢酶的非预期相互作用。
Turk J Med Sci. 2022 Oct;52(5):1425-1447. doi: 10.55730/1300-0144.5482. Epub 2022 Oct 19.
10
Barbaloin: an amazing chemical from the 'wonder plant' with multidimensional pharmacological attributes.芦荟苷:来自“神奇植物”的神奇化学物质,具有多维的药理学特性。
Naunyn Schmiedebergs Arch Pharmacol. 2022 Dec;395(12):1525-1536. doi: 10.1007/s00210-022-02294-4. Epub 2022 Sep 29.
针对 COVID-19 主蛋白酶的虚拟筛选和再利用 FDA 批准的药物。
Life Sci. 2020 Jun 15;251:117627. doi: 10.1016/j.lfs.2020.117627. Epub 2020 Apr 3.
4
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.新型冠状病毒肺炎及相关人类冠状病毒疾病治疗药物和疫苗的研发
ACS Cent Sci. 2020 Mar 25;6(3):315-331. doi: 10.1021/acscentsci.0c00272. Epub 2020 Mar 12.
5
SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat.SARS-CoV-2:一种引发全球威胁的新兴冠状病毒。
Int J Biol Sci. 2020 Mar 15;16(10):1678-1685. doi: 10.7150/ijbs.45053. eCollection 2020.
6
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.2019新型冠状病毒治疗的治疗选择:循证方法
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
7
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
8
The SARS-CoV-2 outbreak: What we know.新型冠状病毒爆发:我们所知道的。
Int J Infect Dis. 2020 May;94:44-48. doi: 10.1016/j.ijid.2020.03.004. Epub 2020 Mar 12.
9
The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和新型冠状病毒(COVID-19)疫情,最新和最大的全球健康威胁:我们从中吸取了哪些教训?
Int J Epidemiol. 2020 Jun 1;49(3):717-726. doi: 10.1093/ije/dyaa033.
10
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒(2019 - 新冠病毒)。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.